Celgene alliance gives VentiRx funding and expertise - and maybe a new owner
This article was originally published in Scrip
Executive Summary
When it came time to evaluate partners for its toll-like receptor 8 (TLR8) agonist VTX-2337, privately-held VentiRx Pharmaceuticals went with Celgene, because of the public company's success in developing cancer therapies and its growing interest in both immunotherapies and the treatment of solid tumours.
You may also be interested in...
Celgene's Partnered Pipeline Delivers Successes And Setbacks
Celgene won the first approval for a drug developed under its aggressive deal-making strategy in 2017 and several potential blockbusters in its partnered pipeline are edging closer to the market. Ozanimod will soon face regulatory approval, but the next-in-line acquired asset GED-0301 had a major setback. Scrip considers the contribution externally derived products have made – and will make – to Celgene’s business.
Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases
EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.
Finance Watch: Ferring Shutters San Diego R&D Site As Even Money-Making Firms Cut Costs
Restructuring Edition: After reporting record revenue, but lower profits due to rising costs, Ferring has decided to consolidate R&D in Europe. Also, Codiak has filed for Chapter 11 bankruptcy and will sell off its assets, while Exicure, Applied Molecular Transport, Gamida Cell and others revealed new job cuts.